ENPICOM Services Neogene Therapeutics with its T Cell Repertoire Sequencing Data Handling and Analysis Solution

UltraSight Raises $13 million to Bring AI Guidance for Cardiac Ultrasound to Patient Point of Care

The Yozma Group Korea, Atain Specialty Insurance Company and the Weizmann Institute of Science participated in the round.

Jon Hopkins New Senior Vice President-Chief Development Officer of Legion Healthcare Partners

Over the past 23 years, Jon has held various positions at Varian Medical Systems including Director of Sales, Americas West & Latin America, Varian Proton Solutions and prior Director of Worldwide Sales, Varian Particle Therapy.

Sinan Batman Appointed CTO of TeraRecon

Batman brings rich industry experience to TeraRecon, including Chief Engineer at Carestream/Kodak Health Group, where he defined the vision for image-centric workflow information systems.

November 5, 2020

ENPICOM B.V., an innovative bioinformatics software engineering company delivering ground-breaking products and customized solutions to decode the immune system and improve human health, today announced the company has entered into a service agreement with Neogene Therapeutics to grant the company access to ENPICOM’s cloud-based IGX Platform to manage, organize, and analyze T cell sequencing data.

ENPICOM has additionally developed a number of customizations making sure that the platform’s functionality fits Neogene’s specific data handling workflow to help Neogene’s research team leverage the full potential of their immune repertoire data.

“We are extremely proud to add Neogene Therapeutics to our IGX Platform customer base. Their recent $110 million Series A shows how important this new type of immunotherapy has become in the last few years,” stated Jos Lunenberg, CEO of ENPICOM.

Dedicated to developing personalized neoantigen T cell receptor (TCR) therapies for cancer, Neogene Therapeutics extensively studies immune repertoires of cancer patients by high-throughput T cell sequencing in order to identify T cell receptor genes with therapeutic value. Personalized neo-antigen TCR therapy is a novel approach to cancer treatment, where a patient’s T cells are genetically engineered with neoantigen specific TCR genes to enable them to identify and destroy tumor cells.

Dr. Carsten Linnemann, CEO of Neogene Therapeutics, added: “ENPICOM and the Neogene team have been collaborating for several years on various projects. ENPICOM has always been a thoughtful and highly reliable partner. It is a pleasure to utilize their innovative and unique IGX Platform.”

Since immune repertoire sequencing implies the generation of large amounts of data, there is a need for specific expertise to efficiently manage and fully exploit the potential of the data collected. ENPICOM’s IGX Platform provides Neogene with an efficient solution to manage and annotate T cell sequencing data.

The IGX Platform comes with powerful data management features and an intuitive user interface out of the box. Its modular, flexible structure allows for further enhancements and customizations. The custom robust workflow of the IGX Platform uniquely positions it to support high-throughput studies required to power Neogene’s research in personalized T cell therapies.



Subscribe to Medical Device News Magazine here.

Related Articles